84 related articles for article (PubMed ID: 11910867)
21. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
[TBL] [Abstract][Full Text] [Related]
22. A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes.
Maxeiner JH; Karwot R; Sauer K; Scholtes P; Boross I; Koslowski M; Türeci O; Wiewrodt R; Neurath MF; Lehr HA; Finotto S
Cancer Res; 2009 Apr; 69(7):3069-76. PubMed ID: 19318584
[TBL] [Abstract][Full Text] [Related]
23. IL-2 responsiveness of CD4 and CD8 lymphocytes: further investigations with human IL-2Rbeta transgenic mice.
Gesbert F; Moreau JL; Thèze J
Int Immunol; 2005 Aug; 17(8):1093-102. PubMed ID: 16037071
[TBL] [Abstract][Full Text] [Related]
24. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
[TBL] [Abstract][Full Text] [Related]
25. Enhancing antitumor immunity: combining IL-12 with TGFbeta1 antagonism.
Fan TM; Kranz DM; Roy EJ
J Immunother; 2007; 30(5):479-89. PubMed ID: 17589288
[TBL] [Abstract][Full Text] [Related]
26. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor.
Marie JC; Liggitt D; Rudensky AY
Immunity; 2006 Sep; 25(3):441-54. PubMed ID: 16973387
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of tolerance induced by TGF beta-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGF beta.
Alard P; Clark SL; Kosiewicz MM
Eur J Immunol; 2004 Apr; 34(4):1021-30. PubMed ID: 15048712
[TBL] [Abstract][Full Text] [Related]
28. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
29. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
[TBL] [Abstract][Full Text] [Related]
30. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma.
Laouar Y; Sutterwala FS; Gorelik L; Flavell RA
Nat Immunol; 2005 Jun; 6(6):600-7. PubMed ID: 15852008
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
[TBL] [Abstract][Full Text] [Related]
32. Dysregulation of IL-15-mediated T-cell homeostasis in TGF-beta dominant-negative receptor transgenic mice.
Lucas PJ; Kim SJ; Mackall CL; Telford WG; Chu YW; Hakim FT; Gress RE
Blood; 2006 Oct; 108(8):2789-95. PubMed ID: 16788095
[TBL] [Abstract][Full Text] [Related]
33. Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-β signaling.
Ansa-Addo EA; Zhang Y; Yang Y; Hussey GS; Howley BV; Salem M; Riesenberg B; Sun S; Rockey DC; Karvar S; Howe PH; Liu B; Li Z
J Clin Invest; 2017 Apr; 127(4):1321-1337. PubMed ID: 28287407
[TBL] [Abstract][Full Text] [Related]
34. Heritable lympho-epithelial thymoma resulting from a transgene insertional mutation.
Nakajima H; Nakajima HO; Soonpaa MH; Jing S; Field LJ
Oncogene; 2000 Jan; 19(1):32-8. PubMed ID: 10644977
[TBL] [Abstract][Full Text] [Related]
35. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
Minev BR; McFarland BJ; Spiess PJ; Rosenberg SA; Restifo NP
Cancer Res; 1994 Aug; 54(15):4155-61. PubMed ID: 7518351
[TBL] [Abstract][Full Text] [Related]
36. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor.
Lucas PJ; Kim SJ; Melby SJ; Gress RE
J Exp Med; 2000 Apr; 191(7):1187-96. PubMed ID: 10748236
[TBL] [Abstract][Full Text] [Related]
37. TGF-beta knockout and dominant-negative receptor transgenic mice.
Letterio JJ; Böttinger EP
Miner Electrolyte Metab; 1998; 24(2-3):161-7. PubMed ID: 9525700
[TBL] [Abstract][Full Text] [Related]
38. Overcoming the hurdles in using mouse genetic models that block TGF-beta signaling.
Sanjabi S; Flavell RA
J Immunol Methods; 2010 Feb; 353(1-2):111-4. PubMed ID: 20060833
[TBL] [Abstract][Full Text] [Related]
39. The phenotype of lymphocytes in a thymoma as studied with monoclonal antibodies.
Woda BA; Bain K; Vander Salm T
Clin Immunol Immunopathol; 1984 Feb; 30(2):197-201. PubMed ID: 6362939
[TBL] [Abstract][Full Text] [Related]
40. TGF-β: guardian of T cell function.
Oh SA; Li MO
J Immunol; 2013 Oct; 191(8):3973-9. PubMed ID: 24098055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
